Varenicline as a Repurposable Drug Candidate for ADRD Prevention
Using the All of Us Research Database, this study found that among older adults initiating smoking cessation therapy, varenicline use was associated with a significantly reduced risk of Alzheimer's disease and related dementias compared to nicotine replacement therapy, supporting its potential as a repurposable drug for ADRD prevention.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
For millions of people, the slow erosion of memory and thinking skills known as Alzheimer's disease and related dementias remains one of the most daunting challenges of modern aging. While researchers have long searched for a cure, the most promising path forward may lie in prevention: finding ways to stop the disease before it ever takes hold. A key piece of this puzzle involves the brain's cholinergic system, a network of nerve cells that uses a chemical messenger called acetylcholine to help us form memories and stay alert. In Alzheimer's, this system often breaks down, leaving the brain struggling to communicate. Because of this, scientists have long wondered if drugs that boost or mimic the action of acetylcholine could protect the brain. At the same time, we know that smoking damages blood vessels and inflames the brain, significantly raising the risk of dementia. Stopping smoking is one of the few proven ways to lower that risk, but the journey to quitting is difficult, and not all methods work equally well for everyone.
A team of researchers recently set out to investigate whether a specific medication used to help people quit smoking, called varenicline, might offer an extra layer of protection against dementia. This drug works by attaching to the same receptors in the brain that nicotine does, but it does so in a way that reduces cravings without delivering the full hit of the drug. The researchers wanted to know if people who took varenicline to quit smoking were less likely to develop dementia over time compared to those who used a different, more common approach: nicotine replacement therapy, which includes patches, gum, and lozenges that deliver small amounts of nicotine to the body. By comparing these two groups, the scientists hoped to see if the specific chemical action of varenicline offered a unique benefit beyond just helping people stop smoking.
To answer this question, the researchers turned to a massive collection of health records from the All of Us Research Program, a national effort to gather diverse health data from one million people. They focused on adults aged fifty and older who had a history of smoking and had started a new course of treatment with either varenicline or nicotine replacement therapy between 2006 and 2023. The team carefully selected only those who had not yet been diagnosed with dementia and ensured they had enough follow-up time to see what happened next. To make a fair comparison, they used a statistical method to pair up individuals from the two groups who were nearly identical in terms of their age, sex, race, health conditions, and other medications they were taking. This process created two groups of 1,758 people each, where the only major difference was the type of smoking cessation medication they had started.
The results of this comparison were striking. Over the course of the study, the group taking varenicline developed dementia at a significantly lower rate than the group using nicotine replacement therapy. The data showed that varenicline use was associated with a hazard ratio of 0.516 for developing dementia compared to nicotine replacement therapy, indicating a strong protective association. This protective effect held true even when the researchers looked at a combined outcome that included both developing dementia and dying during the study period, where varenicline users again showed a clear advantage. The researchers also tracked how long people stayed on their medication and found that those taking varenicline tended to stay on the treatment longer than those using nicotine patches or gum, suggesting better adherence to the regimen. Additionally, while the study noted that smoking behavior after treatment could not be comprehensively or systematically ascertained, descriptive analyses showed directionally consistent signals, with a higher proportion of varenicline users appearing to remain smoke-free based on the absence of smoking-related medical diagnoses in their records.
The study offers a compelling clue that varenicline might do more than just help people quit smoking; it may actively shield the brain from the damage that leads to dementia. The researchers suggest that because varenicline acts on specific receptors in the brain that are involved in memory and learning, it could be providing a direct neuroprotective effect, perhaps by reducing inflammation or supporting the health of nerve cells. This idea aligns with earlier laboratory studies that showed similar drugs could protect brain cells in animal models. However, the researchers are careful to note that their findings do not prove that varenicline is a guaranteed cure or prevention method for everyone. The study was observational, meaning it looked at what happened naturally rather than testing the drug in a controlled experiment, and it relied on medical records that might not capture every detail of a person's smoking habits or lifestyle.
Despite these limitations, the findings are significant enough to warrant further investigation. The study highlights a potential new use for an existing, well-understood medication, a strategy known as drug repurposing. If future clinical trials confirm that varenicline can indeed lower the risk of dementia, it could change how doctors approach both smoking cessation and brain health. For now, the research suggests that for older adults trying to quit smoking, varenicline might offer a dual benefit: helping them break the habit while potentially offering a unique shield for their aging minds. The path forward will require rigorous testing to separate the effects of simply quitting smoking from the specific chemical benefits of the drug, but this study has opened a door to a promising new avenue in the fight against dementia.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.